Abstract 299P
Background
With the increasing proportion of women surviving carcinoma cervix, quality of life becomes an important issue. Most of the diagnosed women belong to the sexually active group (mean age 50 years). Therefore impact on sexual health is vital. Since there are only few studies on the topic, this study is to assess sexual dysfunction issues in patients treated with multimodality therapy using the LENT SOMA scores.
Methods
The study was prospective. A total of 85 patients were accrued comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage III B and 1 stage IV A disease. Sixty six patients were treated with radiotherapy in which 46 patients received chemoradiotherapy and 19 had surgery prior to postoperative radiotherapy. The mean age was 47.81 years with a range of 2568 years. Completion of LENT SOMA scale and Statistical analysis for sexual dysfunction scores was done- stage wise and treatment wise.
Results
Mean subjective sexual function and satisfaction scores was highest in stage IIIA disease (0.0972) while maximum subjective sexual score was seen in stage IIB disease (0.94). Mean objective score VG (Vagina) was highest in stage IVA and maximum score (0.80) was seen in stage IIIB. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients in which gap between treatment and interview was 11 years and maximum score was highest (0.94) in same group. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients who were treated in earlier years when compared with other patients p value-0.093). Sexual function and satisfaction maximum score was highest in combined surgery and radiotherapy group (0.94) and minimum in RT alone group (0.54). The objective mean score VG (Vagina) was highest in combined surgery and radiotherapy group and maximum score(0.80) was highest in the radiotherapy(+chemo) group.
Conclusions
Currently there is no single self-report measure in routine clinical follow use which is easy to complete and incorporates all aspects of sexual health for people affected by cancer. We used LENT SOMA scale in our study, it provides a comprehensive system to assess treatment induced sexual difficulties to score the impact of radiotherapy morbidity in cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract
40P - Intra-tumoral CD3, CD4, and CD8 as prognostic biomarkers in Asian breast cancer
Presenter: Jia Wern Pan
Session: Poster Display
Resources:
Abstract
41P - Brown fat activation demonstrated on FDG PET/CT predicts survival outcome
Presenter: Sonya Park
Session: Poster Display
Resources:
Abstract
42P - A promising anticancer drug for triple-negative breast cancer: OZ-001 suppresses tumor growth by dual targeting STAT3 and calcium signaling
Presenter: Jisun Kim
Session: Poster Display
Resources:
Abstract
43P - Performance evaluation of a combined risk model for breast cancer risk prediction in Indonesian population (TRIP Study)
Presenter: Marco Wijaya
Session: Poster Display
Resources:
Abstract
44P - Pathological complete response to neoadjuvant chemotherapy and outcomes in Her-2 negative locally advanced breast cancer
Presenter: Amrith Patel
Session: Poster Display
Resources:
Abstract
45P - Demographic determinants of pathological complete response after neoadjuvant chemotherapy in breast cancer
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
46P - Predicting toxicity following cancer chemotherapy by detecting transporter gene ABCB1 (C1236T, G2677T/A, C3435CT) polymorphism in breast cancer patients receiving chemotherapy with anthracycline and taxane either sequentially or concomitantly
Presenter: Tanuma Mistry
Session: Poster Display
Resources:
Abstract
47P - Sequencing of chemotherapy and surgery among older triple-negative and HER2-positive breast cancer patients with comorbidities
Presenter: Anvesh Dharanikota
Session: Poster Display
Resources:
Abstract
48P - The impact of preoperative axillary ultrasound on the false negative rate of sentinel lymph node biopsy in post neoadjuvant chemotherapy breast cancer patients
Presenter: Byshetty Rajendar
Session: Poster Display
Resources:
Abstract